Clinical trials: Phase 1
Peanut Allergy
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
This clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.
- Trial name
- NCT05440643
- Testing
- Peanut SLIT-tablet
- Where
- 42 sites in United States, Canada
- Volunteers
- 209 people
- Sponsor
- ALK-Abelló A/S
Hiv
Evaluation of the Preventing AIDS Through Live Movement and Sound (PALMS) Intervention for Minority Adolescents
The purpose of this program evaluation is to determine whether the Preventing AIDS Through Live Movement and Sound (PALMS) group-level intervention is effective in reducing HIV sex risk behaviors and increasing HIV testing of…
- Trial name
- NCT00137644
- Testing
- Preventing AIDS Through Live Movement and Sound (PALMS)
- Where
- United States
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Solid Organ Transplant Complications, Solid Organ Transplant Recipients
Phase I Trial on the Safety of Delayed Infusion of a Naïve T Cell-Depleted Hematopoietic Graft With Memory T Cells in Solid Organ Transplant Recipients
The goal of this clinical trial is to evaluate the safety and feasibility of inducing hematopoietic mixed chimerism to promote immune tolerance and potentially reduce the need for lifelong immunosuppression in pediatric and adult…
- Conditions
- Solid Organ Transplant Complications, Solid Organ Transplant Recipients, Solid Organ Transplant Rejection
- Trial name
- DUALGRAFT (NCT06997471)
- Testing
- Investigational cellular therapy consisting on a HSCT using a graft enriched in CD34+, depleted of naïve T-lymphocytes and supplemented with memory lymphocytes
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Francisco Hernández Oliveros
Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III
Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3.
- Trial name
- NCT05559801
- Testing
- Bone marrow-derived mesenchymal stromal cells (MSCs)
- Volunteers
- 12 people
- Sponsor
- Emory University
Neoplasm
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
The purpose of this study is to determine the dose limiting toxicities and recommended phase 2 dose of SGT-53 alone and in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory solid…
- Trial name
- NCT02354547
- Testing
- SGT-53, Topotecan, Cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- SynerGene Therapeutics, Inc.
Acute Lymphocytic Leukemia
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
The safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double gene deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL)…
- Trial name
- NCT06481735
- Testing
- TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Fludarabine, Cyclophosphamide
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Pediatric Recurrent Central Nervous System Tumors
Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors
The purpose of this research study is to learn about the safety and feasibility of giving a personalized DNA vaccine to people with central nervous system tumors that have returned or have been resistant to treatment.
- Trial name
- NCT03988283
- Testing
- Personalized neoantigen DNA vaccine, Papivax Biotech TDS-IM v2.0, Peripheral blood draw
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Washington University School of Medicine
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL
- Conditions
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma, PTCL
- Trial name
- Phase I/II (NCT06874946)
- Testing
- CD5-targeted CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Acute Lymphoblastic Leukemia, Adult B-Cell
CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia
This is a single-arm, open-label, single-center, phase I/II study to determine the safety and efficacy of CD19 CAR-T(ssCART-19) combined with autologous T cells engineered to express CD19, namely CD19+ feeding T cells (FTCs), as…
- Trial name
- NCT03984968
- Testing
- ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Neuroblastoma, Sarcoma
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
The purpose of this study is to test the manufacturing feasibility and safety of intravenous (IV) administration of B7-H3CART in children and young adult subjects with relapsed and/or refractory solid tumors expressing B7-H3…
- Conditions
- Neuroblastoma, Sarcoma, Osteosarcoma
- Trial name
- NCT06500819
- Testing
- B7-H3CART Dose (Intravenous)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Stanford University
Allergy Amoxicillin, Beta-lactam Allergy Labels
The Implementation and Impact of an Allergy De-Labeling Program in the Emergency Department
Beta-lactams are the most common antibiotics prescribed to children, including penicillin and amoxicillin. They are usually more effective and have fewer side effects than other ty antibiotics.
- Trial name
- NCT06823154
- Testing
- Amoxicillin, Study questionnaire
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- The Hospital for Sick Children
B Cell Lymphoma
Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
This is a single-arm, open-label clinical study evaluating the efficacy and safety of U01 (ssCART-19) in patients with relapsed or refractory B-cell lymphoma.
- Trial name
- NCT07093073
- Testing
- ssCART-19
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Asthma, COPD
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.
- Conditions
- Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis
- Trial name
- NCT04624490
- Testing
- Hyperpolarized Xe129
- Where
- United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Mario Castro, MD, MPH
Methylmalonic Acidemia
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia
This is a study of mRNA-3705 in participants with isolated elevated methylmalonic acid (MMA) due to methylmalonyl-coenzyme A (CoA) mutase (MUT) deficiency.
- Trial name
- NCT04899310
- Testing
- mRNA-3705
- Where
- 11 sites in United States, Canada and 4 more
- Volunteers
- 18 people
- Sponsor
- ModernaTX, Inc.
B-cell Lymphoma
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
This is a single-arm, open-label clinical study evaluating the efficacy and safety of CD20/CD19/CD22 multi-targeted chimeric antigen receptor T-cell (CAR-T) injection in patients with relapsed/refractory B-cell lymphoma.
- Trial name
- NCT07093086
- Testing
- Triple-targeted CAR-T Therapy
- Where
- 2 sites in China
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Race-related Stress, Depression, Anxiety
Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black…
- Conditions
- Race-related Stress, Depression, Anxiety, Quality of Life, Stress Reaction
- Trial name
- ACT for SCD (NCT05685368)
- Testing
- ACT for SCD
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Children's Hospital Los Angeles
Malignant Brain Tumor, Malignant Glioma
Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients
Purpose : the aim of this study is to assess the feasibility and safety of ultrasound-induced opening of the blood-brain barrier (BBB) with the SonoCloud-9 implantable ultrasound device in pediatric patients treated for a…
- Conditions
- Malignant Brain Tumor, Malignant Glioma, Embryonal Tumor
- Trial name
- SONOKID (NCT05293197)
- Testing
- SonoCloud® (9 transducers)
- Where
- 3 sites in France
- Volunteers
- 24 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myocardial Ischemia, Coronary Artery Disease
A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients
This is a multi-centre, open-label, single-dose safety, tolerability and PK-pharmacodynamics (PD) study of the vasodilator regadenoson in 3 paediatric age groups for whom a pharmacologic stress perfusion CMR test is clinically…
- Trial name
- Rapiscan PIP (NCT04604782)
- Testing
- Regadenoson
- Where
- 5 sites in France, Greece and 2 more
- Volunteers
- 54 people
- Sponsor
- GE Healthcare
Epstein-Barr Virus Infection
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in…
- Trial name
- NCT05164094
- Testing
- mRNA-1189
- Where
- 65 sites in United States
- Volunteers
- 867 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita
Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects…
- Conditions
- Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
- Trial name
- NCT07011589
- Testing
- Efgartigimod
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M. Peter Marinkovich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.